A Familiar Chemical with an Unfamiliar Role
For decades, serotonin has been discussed almost exclusively in terms of mood. It is the neurochemical that SSRI antidepressants target, medications taken by an estimated 45 million Americans every year, including brands like Prozac, Zoloft, and Lexapro. But a growing body of research from Columbia University is pointing toward a second, far less understood role for this molecule: accelerating the deterioration of heart valves in certain patients.
ScienceDaily published a synthesis of the Columbia research on July 11, 2026, drawing together findings from a landmark 2023 multicenter study, a 2024 animal experiment, a January 2026 paper in Frontiers in Cardiovascular Medicine, and a 2026 systematic review — all pointing toward the same conclusion: when the serotonin transporter (SERT) is less active than normal, valves may become more vulnerable to a specific form of damage.
Why This Matters
The concern does not apply to every SSRI user. The researchers are careful to point out that tens of millions of people have taken these medications for years without dramatic valve consequences. But the findings raise a question that medicine has not yet fully answered: could a subset of SSRI users — particularly those with existing mitral valve disease and a specific genetic variant — be progressing toward surgery faster than they otherwise would?
The multicenter study, co-led by Columbia's Giovanni Ferrari, PhD, and CHOP's Robert J. Levy, MD, and published in Science Translational Medicine, analyzed clinical data from more than 9,000 patients who had undergone valve repair or replacement surgery for degenerative mitral regurgitation (DMR). Ferrari told Columbia Surgery News that "taking SSRIs was associated with severe mitral regurgitation that needed to be treated with surgery at a younger age than for patients not taking SSRIs."
That is a striking finding — and one that warrants careful framing. The study identifies an association, not a proven cause-and-effect relationship. But the signal is consistent across multiple studies and species.
What We Know So Far
The scientific mechanism at the center of this research involves SERT — the serotonin transporter protein. In normal function, SERT clears serotonin out of the bloodstream after it has done its job. When SERT is less active, serotonin remains available for longer. This is precisely how SSRIs work: they block SERT, increasing serotonin availability in the brain. But serotonin is not only present in the brain — it circulates in the bloodstream and can interact with receptors on heart tissue, including the mitral valve.
Researchers identified genetic variants in the SERT gene region known as 5-HTTLPR that affect SERT activity. A specific variant — called the "long-long" variant, in which a person inherits two copies of the less-active SERT form — appears to make mitral valve cells more sensitive to serotonin-driven damage, specifically excess collagen production and structural thickening.
Patients with DMR who carried the long-long variant required mitral valve surgery more often than those with other variants, suggesting that genetics determines who is most exposed to any serotonin-related valve risk.
A follow-up study published in Frontiers in Cardiovascular Medicine in January 2026 extended the finding to aortic stenosis — a different and more common valve condition in which the aortic valve becomes stiff and narrowed. That study found similar patterns: reduced SERT expression in diseased valve tissue, stronger serotonin receptor signaling, and early scarring that was reduced in mice when a specific receptor was blocked.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study types: Multicenter clinical study (9,000+ patients); animal model experiments; human cell laboratory studies; 2026 systematic review and meta-analysis; January 2026 Frontiers in Cardiovascular Medicine mechanistic study
- Published in: Science Translational Medicine (2023); Frontiers in Cardiovascular Medicine (January 2026); synthesized publicly July 11, 2026
- What the research found: Reduced SERT activity — whether genetic or SSRI-induced — is associated with faster progression of degenerative mitral regurgitation and earlier need for surgery, particularly in patients carrying the long-long 5-HTTLPR genetic variant. A 2026 systematic review reported a significant association between SERT-modifying drugs and heart valve disease with an odds ratio of 2.76.
- What it did not prove: None of this research proves that SSRIs cause heart valve disease. The systematic review covered a broad category of SERT-modifying drugs, not SSRIs specifically, and its authors acknowledged that mechanistic evidence remains limited. Current medical guidance on SSRIs has not changed.
- What readers should know: Patients with a known diagnosis of mitral valve disease who take SSRIs should raise this research with their cardiologist. No one should stop SSRI medication without speaking with a prescribing clinician.
Where the Evidence Stands Today
A 2026 systematic review and meta-analysis examining clinical studies involving medications that modify SERT activity reported a significant association between these drugs and heart valve disease, with an odds ratio of 2.76. For context, an odds ratio compares the probability of an outcome between groups — it does not predict an individual patient's risk, and it does not establish causation.
The review's authors acknowledged that more research is needed to separate the effects of different specific drugs, doses, treatment durations, underlying health conditions, and pre-existing valve abnormalities before any clinical guidance can be issued.
Dr. Ferrari, scientific director of the Cardiothoracic Research Program at Columbia, noted that DMR currently has no pharmacological treatment: "Certain medications can ease the symptoms and prevent complications, but they do not treat the mitral valve. If the degeneration of the mitral valve becomes severe, surgery to repair or replace the valve is needed." This gap — the absence of any drug to slow valve deterioration — is part of what makes the serotonin pathway an attractive area of investigation.
The experimental compound that blocked HTR2B — the receptor implicated in the aortic valve study — helped preserve valve structure in mice. That makes it an intriguing possible drug target, but it is not an approved treatment and has not been tested in human clinical trials.
What This Means for SSRI Users
The Columbia researchers noted in their 2023 study that the cardiac effect of SSRIs has not been as dramatic as the withdrawn diet drugs — such as Fen-Phen, which caused severe valve disease at high doses — given that millions of people have taken SSRIs safely for decades. The effect being studied here is described as "more subtle." Estibaliz Castillero, PhD, a lead researcher at Columbia's Cardiothoracic Research Program, told New York-Presbyterian that "the effect of SSRIs in the cardiac valves has not been as dramatic as the diet drugs considering that millions of people take an SSRI, sometimes for decades, so we wanted to study whether a more subtle effect may be going on in mitral valve disease."
The researchers suggested that additional research may help determine whether DMR patients who respond well to SSRIs should receive more frequent cardiac evaluations, and whether DMR patients not responding well to SSRIs should consider switching to a non-SSRI antidepressant rather than increasing the SSRI dose.
Who Faces the Greatest Risk?
Based on current evidence, the people who may warrant the closest attention are:
- Patients already diagnosed with degenerative mitral regurgitation who are currently taking SSRI antidepressants
- People with a family history of early valve surgery or known mitral valve prolapse who take SSRIs
- Patients carrying the long-long variant of the 5-HTTLPR genetic marker, though genetic testing for this variant is not yet standard clinical practice
- Older adults with multiple cardiometabolic conditions who take SSRIs and have not had recent cardiac evaluation
For the vast majority of SSRI users with no known heart valve abnormality, this research does not currently indicate a need to change medication.
Symptoms and Warning Signs to Watch For
People with degenerative mitral regurgitation may experience:
- Shortness of breath, especially with physical activity or when lying flat
- Fatigue and reduced exercise tolerance
- Heart palpitations or a sensation of a racing or irregular heartbeat
- Swelling in the legs or feet
- A heart murmur detected by a clinician during examination
Many people with early mitral valve disease have no symptoms. Regular cardiac monitoring, especially via echocardiogram, is the primary way to track valve status over time.
If you experience sudden worsening of any of these symptoms, seek medical evaluation promptly. Severe mitral regurgitation can progress rapidly in some patients.
What You Can Do Now
- Do not stop taking your SSRI medication based on this research. The evidence does not support changing antidepressant treatment without speaking to a prescriber.
- If you have a known diagnosis of mitral valve disease or mitral valve prolapse and currently take SSRIs, bring this research to your cardiologist's attention at your next appointment and ask whether any monitoring changes are appropriate.
- If you have a family history of early heart valve surgery and take SSRIs, ask your primary care provider whether a referral to cardiology for baseline evaluation makes sense.
- Patients with mitral valve disease who have not had a recent echocardiogram should discuss scheduling one with their care team, regardless of SSRI use.
- Watch for symptoms of worsening valve function — particularly new or increasing shortness of breath — and report these to your doctor promptly.
Cost and Access: What Patients Should Know
Echocardiograms — the standard imaging tool for monitoring valve disease — are covered under most insurance plans when ordered for an established cardiac diagnosis. For patients without insurance, federally qualified health centers and cardiology clinics at academic medical centers often offer sliding-scale fees.
If you are considering a genetic test for the 5-HTTLPR variant, be aware that this testing is not currently ordered as standard clinical practice for SSRI prescribing or cardiac monitoring, and insurance coverage varies widely. Discuss with your provider whether testing would change your clinical management before ordering it.
What Happens Next
The Columbia research team is expected to continue investigating the HTR2B receptor as a potential drug target that might slow valve deterioration — a treatment class that does not currently exist. Future studies are likely to examine whether the serotonin-valve connection is consistent across different SSRI drugs, different doses, and different patient populations. MedicalDaily will cover significant developments in this research as they emerge.
The Bottom Line
The evidence from Columbia University represents a serious, methodologically rigorous line of investigation, not a reason for alarm, but a reason for informed conversation between patients and their clinicians. If you have both mitral valve disease and are taking an SSRI, that conversation is worth having now. For the vast majority of SSRI users with no known valve abnormality, current evidence does not support changing your medication.
